Sulfathiazole (100 µg/mL in acetonitrile)

Sulfathiazole (100 μg/mL in acetonitrile) is an orally active, endocrine disruptor targeting the steroidogenic pathway, specifically enhancing the activity of CYP19 in human adrenal cancer cells (H295R) and upregulating the mRN expression of CYP17, CYP19, and 3β-HSD. Sulfathiazole (100 μg/mL in acetonitrile) increases the production of 17-estradiol (E2) and has endocrine disrupting effects on aquatic organisms such as the Japanese medaka fish. Sulfathiazole (100 μg/mL in acetonitrile) is also a cathodic corrosion inhibitor. Sulfathiazole (100 μg/mL in acetonitrile) inhibits the corrosion of copper by chloride ions through chemical and physical adsorption on the copper surface, reduces the corrosion current density and shifts the corrosion potential negatively^[1][2][3]. In Vitro:Sulfathiazole (0.02-20 mg/L；48 h) 在人肾上腺癌细胞 (H295R) 实验中可显著增加 17-雌二醇 (E2) 生成、芳香化酶 (CYP19) 活性及 CYP17、CYP19、3βHSD 等类固醇生成相关基因的 mRNA 表达^[1]。
Sulfathiazole 能有效抑制铜在 0.1 M NaCl 溶液中的腐蚀，抑制效率随浓度升高可达 80% 以上^[3]。 In Vivo:Sulfathiazole (50 mg/L、500 mg/L；水体暴露；每日喂食；14 d) 在雄性日本青鳉鱼 (Oryzias latipes) 模型中可显著提高血浆中 17-雌二醇 (E2) 浓度^[1]。
Sulfathiazole (1%；混入纯化饲料；每日摄入) 在断奶期及断奶后不久的 Wistar 和 Osborne-Mendel 品系白化大鼠模型中导致骨髓中多形核中性粒细胞、杆状核细胞和晚幼粒细胞减少，骨骼肌坏死和钙化，肺/冠状动脉/肾动脉钙化或玻璃样变，肝细胞水样变性和局灶性透明坏死，肾上腺皮质细胞透明坏死，甲状腺增生，以及皮下组织、体腔和器官出血^[2]。